The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | The combination of sonrotoclax and zanubrutinib in MCL and CLL
In this video, Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Alfred Hospital and Monash University, Melbourne, Australia, briefly comments on the combination of sonrotoclax and zanubrutinib for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Although the combination has been more extensively studied in CLL, it has shown encouraging efficacy and safety in a Phase I trial in MCL (NCT04277637), inducing high rates of complete remission (CR).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, sonrotoclax is a second generation BCL2 inhibitor. It’s about 10 times more potent than venetoclax. And we have actually studied the combination of zanubrutinib and sonrotoclax in multiple diseases including CLL and MCL. Specifically MCL, the combination is really well tolerated. It generates high response rates, but this is in the context of a Phase I combination study so mature data is still lacking...
So, sonrotoclax is a second generation BCL2 inhibitor. It’s about 10 times more potent than venetoclax. And we have actually studied the combination of zanubrutinib and sonrotoclax in multiple diseases including CLL and MCL. Specifically MCL, the combination is really well tolerated. It generates high response rates, but this is in the context of a Phase I combination study so mature data is still lacking. There is probably more data on the combination in CLL because larger patients have been treated in the Phase I and the phase three study has actually finished accrual and from the CLL point of view the results actually look substantially better than Ibrutinib and venetoclax with an MRD clearance rate of 93% compared to 75% so we really I really think that sonrotoclax plus zanubrutinib will be the next generation of second generation, second generation dual targeted therapy and will probably take over Ibrutinib venetoclax.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
